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High-mannose (Man9GlcNAc2) is the main carbohydrate unit present in viral envelope glycoproteins such
as gp120 of HIV and the GP1 of Ebola virus. This oligosaccharide comprises the Man9 epitope conjugated
to two terminal N-acetylglucosamines by otherwise rarely-encountered β-mannose glycosidic bond.
Formation of this challenging linkage is the bottleneck of the few synthetic approaches described to
prepare high mannose. Herein, we report the synthesis of the Man9 epitope with both alpha and beta
configurations at the reducing end, and subsequent evaluation of the impact of this configuration on
binding to natural receptor of high-mannose, DC-SIGN. Using fluorescence polarization assays, we
demonstrate that both anomers bind to DC-SIGN with comparable affinity. These relevant results there-
fore indicate that the more synthetically-accesible Man9 alpha epitope may be deployed as ligand for
DC-SIGN in both in vitro and in vivo biological assays.
Introduction
Carbohydrates are ubiquitous in nature and participate in
many biological events relevant to health and disease, such as
cell growth and differentiation, fertilization, inflammation,
tumour progression and metastasis, viral infection, and many
others.1 The function of carbohydrates in these processes
results from interactions with specific receptors, mainly pro-
teins known as lectins.2 Carbohydrate–protein interactions are
characterised by a high selectivity and a low affinity, the latter
of which is compensated by multivalent interactions resulting
from the presentation of multiple copies of the carbohydrate
epitopes and receptors in nature.3 Understanding carbo-
hydrate-mediated processes therefore requires the accessibility
of multivalent carbohydrate platforms capable of intervening
with these processes.4–6
High-mannose (Man9GlcNAc2) is a complex relevant
N-glycan present in several viral envelope glycoproteins
(Fig. 1). This sugar plays a crucial role during the attachment
of pathogens to cells in the first stages of the infection process
through the interaction with the DC-SIGN (Dendritic Cell-
Specific ICAM-3 Grabbing Non-integrin) receptor, found in
lipid patches at the dendritic cell (DC) surface.7 In particular,
gp120 of HIV-1 has an average of 24 N-linked glycans clustered
on the protein surface, of which 53–76% are high-mannose
derivatives.8 This cluster presentation is fundamental to the
efficient interaction with DC-SIGN.
Fig. 1 Chemical structure of high-mannose and its constitutive parts,
the beta Man9 and the GlcNAc2 epitopes.
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Towards better understanding the recognition process
between high-mannose and DC-SIGN, several multivalent
systems have been envisaged. However, the structural complex-
ity of the constituent sugars and the difficulty of obtaining
sufficient quantities of pure material from natural sources
renders the preparation of multivalent systems carrying the
natural beta epitope rather challenging. In fact, very few
examples are reported in the literature describing the synthesis
of Man9 and high-mannose multivalent systems.
9–11 In this
context, different approaches have been developed for the
preparation of simpler compounds that mimic the multivalent
presentation of the sugar found in nature. Small fragments of
the Man9 epitope have been synthesised and evaluated in
different glycomimetic systems in pursuit of sugars simpler
than Man9 but with reasonable binding affinities for
DC-SIGN.12–15 Recently, we have developed a straightforward
synthetic strategy for the preparation of the Man9 epitope with
the natural beta configuration at the reducing end.16 Although
the synthesis that we have described is competitive with those
published previously by other laboratories, the preparation of
the β-mannose unit remains the limiting step. The synthesis of
the appropriately-functionalised beta-mannose monosacchar-
ide building block, required to perform the necessary glycosy-
lation steps towards the preparation of the nonasaccharide,
demands eleven synthetic steps with a global yield of 43%
from S-tolyl-α-D-mannopyranoside.16 As a possible solution,
we considered whether the more synthetically-accessible
α-mannose analogue would provide a similar affinity to
DC-SIGN than the beta anomer, therefore circumventing the
requirement for the complicated β-mannose building block, in
the preparation of the corresponding carbohydrate multivalent
systems.
To evaluate our proposed strategy, we have synthesised the
alpha and beta anomers of the Man9 epitope and the corres-
ponding trivalent glycocluster to examine the differences in
binding affinities to the DC-SIGN receptor using a fluorescence
polarization assay.
Results and discussion
Preparation of Man9 epitopes and glycoclusters
The synthesis of beta Man9 using a convergent straightforward
synthetic strategy was previously described by our laboratory.16
In this work, we used the same strategy to prepare the corres-
ponding alpha anomer.
The di-, penta-, and trisaccharides building blocks were
common intermediates for both anomers, (Fig. 2) being the
mannose of the reducing end with the alpha configuration in
the anomeric position prepared as described in Scheme 1.
The synthesis of the appropriately-protected reducing end
mannose was achieved as depicted in Scheme 1, starting from
the previously described mannosyl derivative 5.17 Mannose 5
was orthogonally protected using a consecutive approach, per-
forming purification only at the final step. Positions 4 and 6
were protected via the formation of the benzylidene acetal by
subjecting 5 to benzaldehyde dimethyl acetal and camphorsul-
fonic acid (CSA). Subsequently, position 3 was protected as the
p-methoxybenzy ether, via the initial formation of a tin acetal
between position 2 and 3, followed by reaction with p-methoxy-
benzyl chloride (PMBCl) and tetrabutyl ammonium iodine
(TBAI). The free OH in position 2 was then protected by ben-
zoylation with benzoyl anhydride in the presence of triethyl
amine and a catalytic amount of dimethylamino pyridine
(DMAP). Finally, the position 3 was selectively deprotected
with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) to yield
the target mannose derivative 6 in 26% overall yield from
mannose 5 following final chromatographic purification.
With the monosaccharide 6 in hand, glycosylation with the
previously synthesised trisaccharide 7 and pentasaccharide
8,16 enabled the formation of the protected Man9 nonasacchar-
ide 11 (Scheme 2).
The glycosylation between trisaccharide 7 and mannose
derivative 6 was performed using N-iodo succinimide and tri-
fluoromethanesulfonic acid as the glycosylation promotor to
obtain tetrasaccharide 9 in 88% yield. Next, the benzylidene
acetal was removed in acidic media using p-TsOH to afford the
tetrasaccharide 10 (bearing unprotected hydroxyl groups at
positions 4 and 6 of the terminal mannose at the reducing
end) in 78% yield. The final glycosylation between tetrasac-
charide 10 and pentasaccharide 8 took place only at the posi-
tion 6 hydroxyl group of the acceptor, since this is more reac-
tive than the sterically hindered hydroxyl group at position 4.
This glycosylation was carried out using the same conditions
Fig. 2 Retrosynthetic scheme for the preparation of αMan9 and βMan9.
Scheme 1 Consecutive synthesis of mannose derivative 6.
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as above to yield the protected nonasaccharide 11 in 73%
yield. The nonasaccharide 11 was characterised by 1H and 13C
NMR and ESI-MS. Finally, global deprotection step with
NaOMe and 2 M NaOH in MeOH and toluene cleaved all
O-benzoyl groups affording the αMan9 12 in excellent yield
(Scheme 2). In this way, the synthesis of the alpha anomer of
Man9 was achieved in an expedient manner through a conver-
gent strategy. Both Man9 epitopes (alpha and beta) were pre-
pared with a short spacer at the anomeric position functiona-
lised with a terminal azido group. This group permits conju-
gation to multivalent scaffolds using the Cu(I) azide–alkyne
cycloaddition (CuAAC) reaction.20,21
To examine the effect that the multivalent presentation has
on the binding DC-SIGN to both anomers, we prepared the tri-
valent glycoclusters with the alpha and beta Man9 epitopes
(Scheme 3).
For this purpose, we employed a trialkynylated pentaerythri-
tol scaffold, frequently used for the preparation of carbo-
hydrate multivalent systems by our group. This scaffold 14 was
prepared in two steps from pentaerythritol as previously
reported.18 The coupling of αMan9 and βMan9 ligands was
then carried out via a click chemistry19 CuAAC reaction pro-
moted by CuSO4, sodium ascorbate and tris[(1-benzyl-1H-1,2,3-
triazol-4-yl)methyl]amine (TBTA) under mild conditions to
obtain the corresponding trivalent glycoclusters. These multi-
valent systems were purified by treatment with Quadrasil MP
resin to remove the copper catalyst and by G50 Sephadex
chromatography to afford the glycoclusters 15 and 16 in good
yields (Scheme 3). The final step was the substitution of the
chlorine atom for an azido group at the end of the linker at the
focal position of the scaffold. This reaction was performed
using an excess of NaN3 in DMF at 70 °C for two days furnish
azido-functionalised glycoclusters 17 and 18 in excellent yields.
Finally, it was necessary to introduce a chromophore for the
fluorescence polarization assays. An alkynyl derivative of fluor-
escein, the commercially available FAM-alkyne 6-isomer 19,
was therefore conjugated to the αMan9 12, the βMan9 13, and
their corresponding trivalent glycoclusters 17 and 18, respect-
ively, by a CuAAC click reaction promoted by CuBr and TBTA
in DMSO at room temperature (Scheme 4).
The compounds were treated with Quadrasil MP resin and
then, submitted to a LH20 Sephadex chromatography to
deliver the fluorescently-labelled compounds 20, 21, 22 and 23
in excellent yields.
With the fluorescent tool compounds prepared, we evalu-
ated their capacity to interact with DC-SIGN, the natural recep-
tor of this Man9 ligand.
Fluorescence polarization assays
Fluorescence polarization is widely used to study binding
events owing to several advantages of this technique.22,23 The
assay requires only small quantities of ligands and receptors,
is well suited for high-throughput screening and does not
require the attachment of any of the partners to a surface,
allowing ligands and receptors diffuse freely in solution. In
particular, fluorescence polarization experiments have been
successfully employed in the analysis of carbohydrate–protein
interactions.24–27 Thus, we selected this assay to evaluate the
binding affinity of our alpha and beta epimers of Man9 (20
and 21) and their corresponding multivalent systems (22 and
23) for DC-SIGN using the tetravalent Extracellular Domain
(ECD) of the lectin. For this, we have used a microtiter plate
where different concentrations of the protein (DC-SIGN ECD),
ranging from 75 nM to 28 µM in Tris buffer, were added to the
Scheme 2 Synthesis of the αMan9 12.
Scheme 3 Synthesis of the trivalent glycoclusters 17 and 18.
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wells containing a fixed final 10 nM concentration of appropri-
ate fluorescent ligands (20–23). We observed an increase in the
fluorescence polarization value with increasing protein con-
centrations, demonstrating that the fluorescence ligands
bound to DC-SIGN ECD. The resulting Langmuir isotherm
curves are represented in Fig. 3. From these curves, the KD of
the binding process for each ligand was calculated. For the α
and β anomers of Man9, similar values of KD, (5.2 ± 1.2 and 4.6
± 1.3 μM, respectively) were found demonstrating that the con-
figuration of the anomer in the mannosyl unit at the reducing
end of the oligosaccharide does not play a critical role in the
binding process.
In order to evaluate the influence of the anomer configur-
ation when the Man9 ligand is presented in a multivalent
scaffold, fluorophore labelled glycoclusters 22 and 23 were
tested in the fluorescence polarization assays (Fig. 3). In this
case, the KD were one order of magnitude lower than the data
found for the monovalent systems, indicating a clear multi-
valent effect (0.53 ± 0.09 and 0.37 ± 0.04 μM for the trivalent
αMan9 and βMan9, respectively). Again, no significant differ-
ences between the dissociation constants of the two anomers
were found as in the case of the monovalent ligands.
Conclusions
The stereochemical configuration of sugars is fundamental to
their selective recognition by lectins. Indeed, just a simple
difference in the configuration of one position can drive the
recognition by one specific lectin, e.g. glucose (with all OH
groups in equatorial disposition) versus galactose (which bears
an axial OH at C4). Furthermore, the configuration of the gly-
cosidic bonds between the monosaccharidic units that form
an oligosaccharide are relevant for their recognition and func-
tion. In the case of high mannose, all the mannoses of the
Man9 epitope display the alpha configuration of the glycosidic
bonds, as usual for this type of sugar. However, the linkage
between the Man9 epitope and the GlcNAc disaccharide exhi-
bits a beta configuration. This glycosidic bond configuration is
rare for mannoses and presents a significant hurdle towards
addressing this bond configuration via chemical synthesis. All
N-glycans have this moiety as connection with the corres-
ponding Asn in the N-glycan proteins. This specific arrange-
ment is critical for the proper orientation of the mannosyl
cluster, providing a rigid structure on the protein surface to
optimize the binding to DC-SIGN. However, when new glyco-
multivalent systems are designed, the glycan epitope is nor-
mally conjugated to the multivalent scaffold with a flexible
Scheme 4 Synthesis of fluorescence labelled compounds 20, 21, 22
and 23.
Fig. 3 Langmuir isothermal curves of binding between DC-SIGN ECD
and fluorescence compounds: (a) αMan9 (20); (b) βMan9 (21); (c) trivalent
glycocluster 22; and (d) trivalent glycocluster 23.
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linker and therefore the specific orientation provided by the
beta-mannose linkage is likely not necessary. To demonstrate
this hypothesis, we have synthesised the Man9 epitope of high
mannose with alpha and beta configuration in the terminal
mannose at the reducing end (20 and 21) and the corres-
ponding trivalent glycoclusters (22 and 23). These ligands were
labelled with a fluorescein derivative and their binding to
DC-SIGN evaluated by fluorescence polarization assays. Our
findings have shown that the configuration, alpha or beta, of
the anomeric position of the terminal mannose does not influ-
ence in the binding affinity for the natural receptor DC-SIGN
and therefore they can be used interchangeably, meaning the
more synthetically-accessible alpha-linked epimers can be
deployed instead of the more challenging natural beta ana-
logues. We anticipate this knowledge is of key relevance in the
design of new glycosystems of high mannose, since notably
reduces the complexity, the time and the cost of the glycan
synthesis by circumventing the synthetic bottleneck of the beta
mannose preparation.
Experimental
Materials and methods
Solvents were HPLC grade and used as received unless other-
wise stated. Size exclusion chromatography was performed
with Sephadex LH20, G-25 and G-50 (GE Healthcare). Thin-
layer chromatography (TLC) was performed on silica plates
(Merck). Reagents and QuadraSil® MP were purchased from
Sigma Aldrich. 2-Azidoethyl α-D-mannopyranoside17 and trialk-
ynylated scaffold 14 18 were synthesised as previously
described. NMR experiments were performed using a Bruker
Advance DRX 400 instrument. NMR chemical shifts are
reported in ppm (δ units) downfield from the CDCl3 signal or
the HOD peak (D2O). 2D experiments (COSY and HSQC) were
performed when necessary. NMR spectra were analysed with
MestreNova software.
Synthesis of ligands
2-Azidoethyl 2-O-benzoyl-4,6-O-benzylidene-α-D-mannopyra-
noside (6). To a solution of 2-azidoethoxy-α-D-mannopyranose
(5) (800 mg, 3.21 mmol) in CH3CN (8 mL), CSA (186 mg,
0.8 mmol) and benzaldehyde dimethyl acetal (0.5 mL,
3.55 mmol) were added at rt. The reaction mixture was stirred
overnight and the mixing became solidified during addition of
the reagent, which indicates the progress of the reaction. The
reaction mixture was quenched with Et3N (250 μL) and dis-
solved in excess of EtOAc and water. The reaction mixture was
extracted twice with EtOAc and the combined organic layers
were dried over anh. MgSO4, filtered and concentrated under
vacuum. After being dissolved in anh. toluene (29 mL), dibutyl-
tin oxide (879 mg, 3.55 mmol) was added to the resulting
mixture containing the 4,6-O-benzylidene derivative. The reac-
tion mixture was kept under reflux at 110 °C for 4 h, cooled to
rt and PMBCl (0.5 mL, 3.55 mmol) and TBAI (370 mg,
3.55 mmol) were added to it under Ar atmosphere. The reac-
tion mixture was kept under reflux at 110 °C for 1 h. After
removal the solvent, the crude was diluted with CH2Cl2 and
washed with water. The organic layer was dried over anh.
MgSO4, filtered and concentrated under vacuum. To the result-
ing mixture containing 4,6-O-benzylidene-3-O-p-methoxybenzyl
derivative in CH2Cl2 (15 mL), Bz2O (1.5 g, 6.42 mmol), Et3N
(1.3 mL, 9.63 mmol) and a catalytic amount of DMAP were
subsequently added and the reaction was stirred at rt for 1 h.
The reaction mixture was washed with NaHCO3 sat. aq. soln.
The organic phase was dried over anh. MgSO4, filtered and
concentrated under vacuum. Finally, to a stirred solution of
the α-D-mannoside derivative in CH2Cl2 (70 mL) and water
(2.7 mL), DDQ (2.23 g, 9.63 mmol) was added at rt. After 1 h,
NaHCO3 sat. aq. soln. was added, and the mixture was
extracted with CH2Cl2. The extract was washed several times
with NaHCO3 sat. aq. soln. and then dried over anh. MgSO4,
filtered and concentrated under vacuum. The crude was puri-
fied by column chromatography on silica gel (EtOAc/n-hexane
1 : 3) to give the compound 6 (320 mg, 0.72 mmol, 26%) as a
colourless oil. [α]D = −37 (c 1.00, CHCl3). 1H-NMR (400 MHz,
CDCl3) δ: 8.11 (m, 2H, H–Ar), 7.60 (m, 1H, H–Ar), 7.56–7.45
(m, 4H, H–Ar), 7.43–7.35 (m, 3H, H–Ar), 5.67 (s, 1H, Hacetal),
5.52 (dd, J2,3 = 3.6, J2,1 = 1.6 Hz, 1H, H-2), 5.01 (d, J1,2 = 1.6 Hz,
1H, H-1), 4.41 (dt, J3,4 = 9.6, J3,2 = 3.9 Hz, 1H, H-3), 4.33 (dd,
J6a,6b = 9.9, J6a,5 = 4.4 Hz, 1H, H-6a), 4.06 (t, J4,3 = J4,5 = 9.5 Hz,
1H, H-4), 4.03–3.84 (m, 3H, H-5, H-6b, H-1′a), 3.73–3.63 (m,
1H, H-1′b), 3.55–3.40 (m, 2H, H-2′), 2.32 (d, JOH,3 = 4.2 Hz, 1H,
OH). 13C-NMR (100 MHz, CDCl3) δ: 166.0, 137.1, 133.5, 129.9,
129.5, 129.3, 128.5, 128.3, 126.3, 102.2, 98.7, 79.2, 72.5, 68.7,
67.1, 66.9, 63.8, 50.4. ESI-MS m/z calcd for C22H23N3O7: 441.2;
found: 464.2 [M + Na]+.
Tetrasaccharide 9. To a solution of acceptor 6 (49 mg,
0.11 mmol), donor 7 (275 mg, 0.17 mmol) and 4 Å molecular
sieves in anh. CH2Cl2 (5.8 mL) were added and the mixture
was stirred at −20 °C for 30 min. Then, NIS (39 mg,
0.17 mmol) and TfOH (2.9 μL, 0.03 mmol) were added and the
reaction was stirred at −20 °C for 15 min. The reaction was
quenched with NaHCO3 sat. aq. soln. The reaction mixture was
filtered through Celite and washed several times with CH2Cl2.
The organic layer was washed with Na2S2O3 sat. aq. soln. and
then dried over anh. MgSO4, filtered and concentrated under
vacuum. The crude was purified by column chromatography
on silica gel (EtOAc/n-hexane 1 : 2 to 1 : 1.25) to give the tetra-
saccharide 9 (193 mg, 0.10 mmol, 88%) as a white solid. [α]D =
−22 (c 1.00, CHCl3). 1H-NMR (400 MHz, CDCl3) δ: 8.22 (m, 1H,
H–Ar), 8.19–8.12 (m, 2H, H–Ar), 8.09–7.92 (m, 7H, H–Ar),
7.92–7.81 (m, 7H, H–Ar), 7.76–7.68 (m, 2H, H–Ar), 7.64–7.19
under CDCl3 (m, 36H, H–Ar), 7.14–6.95 (m, 4H), 6.78 (m, 1H),
6.05–5.81 (m, 5H), 5.79–5.69 (m, 2H), 5.64 (dd, J = 9.2, J = 3.1
Hz, 1H), 5.57 (s, 1H, H-1), 5.49 (br s, 1H, Hacetal), 5.35 (s, 1H,
H-1), 5.05 (d, J = 1.5 Hz, 1H, H-1), 4.91 (s, 1H, H-1), 4.72–4.50
(m, 4H), 4.47 (t, J = 2.8 Hz, 1H), 4.38 (m, 1H), 4.35–4.13 (m,
4H), 4.07–3.94 (m, 3H), 3.94–3.79 (m, 3H), 3.65 (m, 1H), 3.35
(m, 2H). 13C-NMR (100 MHz, CDCl3) δ: 166.4, 166.0, 165.9,
165.8, 165.5, 165.3, 165.3, 165.2, 165.2, 165.0, 164.8, 137.0,
133.7, 133.5, 133.3, 133.2, 133.1, 133.1, 133.1, 133.0, 132.8,
Paper Organic & Biomolecular Chemistry
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130.1–129.6, 129.3, 129.2, 129.2, 129.1, 128.9–128.3 101.9,
99.8, 90.1, 79.1, 71.9, 71.4, 70.4, 70.1, 69.8, 69.7, 69.5, 68.8,
67.6, 67.2, 67.0, 66.3, 64.1, 63.6, 63.5, 62.9, 62.5, 50.4. ESI-MS
m/z calcd for C110H93N3O32: 1967.6; found: 1990.4 [M + Na]
+.
ESI-HRMS m/z calcd for C110H93N3O32Na [M + Na]
+: 1990.5634;
found: 1990.5609
Tetrasaccharide 10. p-Toluenesulfonic acid monohydrate
(25 mg, 0.13 mmol) was added to a stirred solution of tetrasac-
charide 9 (173 mg, 0.09 mmol) in CH3CN (4.4 mL) at rt. After
24 h, the reaction mixture was quenched with Et3N (30 μL) and
concentrated under vacuum. The residue was purified by
column chromatography on silica gel (acetone/toluene 1 : 5) to
give the tetrasaccharide 10 (130 mg, 0.07 mmol, 78%) as a
white amorphous solid. [α]D = −15 (c 1.00, CHCl3). 1H-NMR
(400 MHz, CDCl3) δ: 8.14 (m, 2H, H–Bz), 8.07–7.93 (m, 13H,
H–Bz), 7.90–7.82 (m, 4H, H–Bz), 7.70 (m, 2H, H–Bz), 7.61–7.18
under CDCl3 (m, 34H, H–Bz), 6.13 (t, J = 10.2 Hz, 1H),
6.03–5.90 (m, 3H), 5.84–5.72 (m, 2H), 5.67–5.57 (m, 3H, 1H-1),
5.52 (d, J = 1.6 Hz, 1H, H-1), 5.09 (br s, 1H, H-1), 5.00 (d, J = 1.7
Hz, 1H, H-1), 4.73–4.31 (m, 12H), 4.31–4.15 (m, 2H), 4.01 (m,
2H), 3.95–3.78 (m, 3H), 3.59 (dt, J = 10.4, 4.8 Hz, 1H), 2.34 (m,
2H). 13C-NMR (100 MHz, CDCl3) δ: 166.4, 166.3, 166.0, 165.9,
165.7, 165.5, 165.2, 164.9, 133.6, 133.5, 133.4, 133.3, 133.2,
133.0, 130.2–129.8, 129.6, 129.5, 129.4, 129.3, 129.1, 129.0,
128.9, 128.6–128.4, 100.8, 99.4, 98.1, 76.4, 73.3, 72.4, 70.5,
70.3, 69.9, 69.7–69.6, 69.4, 68.2, 67.8, 67.0, 66.6, 63.9–63.8,
62.6, 62.3, 50.4 (C-2′). ESI-MS m/z calcd for C103H89N3O32:
1879.5; found: 962.5 [M + Na]+. ESI-HRMS m/z calcd for
C103H89N3O32Na [M + Na]
+: 1902.5321; found: 1902.5307.
αMan9 protected (11). To a solution of acceptor 10 (110 mg,
0.06 mmol), donor 8 (228 mg, 0.09 mmol) and 4 Å molecular
sieves in anh. CH2Cl2 (4.1 mL) were added and the mixture
was stirred at −20 °C for 30 min. Then, NIS (42 mg,
0.09 mmol) and TfOH (3.1 μL, 17.55 μmol) were added and the
reaction was stirred at −20 °C for 15 min. The reaction was
quenched with NaHCO3 sat. aq. soln. The reaction mixture was
filtered through Celite and washed several times with CH2Cl2.
The organic layer was washed with Na2S2O3 sat. aq. soln. and
then dried over anh. MgSO4, filtered and concentrated under
vacuum. The crude was purified by column chromatography
on silica gel (EtOAc/n-hexane 4 : 5 → 1 : 1) to give the nonasac-
charide 11 (185 mg, 0.04 mmol, 73%) as a white solid. [α]D =
−19 (c 1.00, CHCl3). 1H-NMR (400 MHz, CDCl3) δ: 8.30–7.67
(m, 52H, HBz), 7.56–7.18 (m, 80H, HBz), 6.99 (m, 2H, HBz),
6.81 (t, J = 7.5, 1H, HBz), 6.22–5.80 (m, 16H), 5.55 (s, 1H, H-1),
5.46 (m, 2H, 2H-1), 5.32 (s, 1H, H-1), 5.18 (s, 1H, H-1), 5.05 (m,
2H, 2H-1), 4.74–4.02 (m, 36H, H-1, H-1), 3.84–3.72 (m, 2H),
3.49–3.32 (m, 3H). 13C-NMR (100 MHz, CDCl3) δ: 166.5, 166.4,
166.4, 166.3, 166.1, 166.0, 165.8, 165.6, 165.6, 165.4, 165.4,
165.3, 165.0, 165.0, 164.8, 164.8, 164.6, 133.5, 133.4, 133.4,
133.2, 133.2, 133.1, 130.2–129.5, 129.5, 129.5, 129.3, 129.2,
129.2, 129.0, 129.0, 128.9, 128.9, 128.7–128.3, 101.1, 100.9,
100.3, 99.9, 99.5, 98.5, 97.7, 97.5, 78.2, 77.9, 75.6, 72.4, 72.2,
71.9, 71.1, 70.8, 70.5, 70.1–69.4, 68.9, 68.1, 68.0, 67.7,
67.3–67.0, 66.6, 66.4, 66.1, 63.7, 63.5, 63.1, 62.6, 62.4, 50.4.
ESI-MS m/z calcd for C245H203N3O73: 4354.2; found: 2200.1
[M + 2Na]2+ and 1473.5 [M + 3Na]3+. ESI-HRMS m/z calcd for
C245H203N3O73Na [M + 2Na]
2+: 2189.1115; found: 2189.1088.
αMan9 (12). To a solution of compound 11 (166 mg,
0.04 mmol) in MeOH/toluene (4 : 1, 1.7 mL), NaOMe (11 mg,
0.20 mmol) and a NaOH 2 M solution (0.7 mL) were added
and the reaction was stirred at 50 °C for 5 h. After neutraliz-
ation with Amberlite IR-120H+, the solution was filtered and
concentrated. The crude was purified by size-exclusion chrom-
atography (Sephadex G-25, H2O/MeOH 9/1), giving Man9 (12)
(55 mg, 0.04 mmol, 93%) as a white amorphous solid.
1H-NMR (400 MHz, D2O) δ: 5.40 (s, 1H, H-1), 5.33 (s, 1H, H-1),
5.30 (s, 1H, H-1), 5.15 (s, 1H, H-1), 5.08–5.01 (m, 3H, 3 × H-1),
4.88 (s, 1H, H-1), under D2O (1H, H-1), 4.19–3.60 (m, 58H).
13C-NMR (100 MHz, D2O) δ: 102.2, 100.8, 100.6, 100.0, 99.5,
98.0, 78.8–78.5, 73.2, 73.2, 72.7, 71.1, 71.1, 70.3–70.0, 69.6,
66.9, 66.8, 66.6, 65.7, 65.5, 65.2, 61.2–61.0, 50.2. ESI-MS m/z
calcd for C56H95N3O46: 1545.5; found: 1568.2 [M + Na]
+, 795.5
[M + 2Na]2+.
D3-αMan9-Cl (15). Nonasaccharide 12 (22.0 mg, 14.23 μmol)
and [2-[2-(2-chloroethoxy)ethoxy]ethoxy]ethoxymethyl trikis(2-
propyniloxymethyl)-methane (14) (1.6 mg, 3.59 μmol) were dis-
solved in H2O/DMSO (1 : 1, 0.5 mL). Fresh solutions of
CuSO4·5H2O (1.80 μmol), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)
methyl]amine (TBTA) (3.59 μmol) and sodium ascorbate
(5.39 μmol) were added to a sealed microwave vial. The solu-
tion was heated at 60 °C in a microwave oven for 30 min. A
metal scavenger resin, QuadrasilMP, was added to the reaction
solution and stirred for 20 min at rt. After that, the mixture
was filtered and the resulting solution was purified by size-
exclusion chromatography (Sephadex G-50, H2O/MeOH 9 : 1)
yielding the glycocluster 15 (12 mg, 2.37 μmol, 66%) as a white
amorphous solid. 1H-NMR (400 MHz, D2O) δ: 8.06 (s, 3H,
Htriazole), 5.41 (br s, 3H, 3H-1), 5.37–5.27 (m, 6H, 6H-1), 5.15
(br s, 3H, 3H-1), 5.09–5.02 (m, 9H, 9H-1), under D2O (6H,
6H-1), 4.67 (m, 3H, O CH2CHHN), 4.57 (br s, 3H,
OCHHCtriazole), 4.14–3.62 (m, 198H).
13C-NMR (100 MHz, D2O)
δ: 144.2, 125.4, 102.2, 100.7, 99.8, 99.5, 98.0, 78.8–78.4,
73.3–73.2, 72.7, 72.0, 71.1–71.0, 70.8, 70.3, 70.0, 70.0, 69.7,
69.6, 69.5, 66.9, 66.8, 65.9, 65.8, 65.6, 65.4, 65.2, 64.8, 63.4,
62.5, 61.0, 50.1, 43.2. ESI-MS m/z calcd for C191H320N9O145Cl:
5080.7; found: 2562.9 [M + 2Na]2+, 1715.5 [M + 3Na]3+, and
1295.7 [M + 4Na]4+.
D3-αMan9-N3 (17). To a solution of glycocluster 15 (9.0 mg,
1.77 μmol) in DMF (1 mL) sodium azide (1.2 mg, 17.71 μmol)
was added. The mixture was stirred at 70 °C for 2 days. After
that time, the solvent was evaporated under vacuum and the
crude was purified using Amicon Ultra-15 centrifugal filters
(MWCO 3 kDa), yielding the glycocluster 17 (9 mg, 1.77 μmol,
quant.) as a white amorphous solid. 1H-NMR (400 MHz, D2O)
δ: 8.06 (s, 3H, Htriazole), 5.41 (br s, 3H, 3H-1), 5.35–5.29 (m, 6H,
6H-1), 5.15 (br s, 3H, 3H-1), 5.07–5.03 (m, 9H, 9H-1), under
D2O (6H, 6H-1), 4.67 (m, 3H, OCHHCH2N), 4.58 (br s, 3H,
OCHHCtriazole), 4.14–3.60 (m, 198H).
13C-NMR (100 MHz, D2O)
δ: 144.2, 125.5, 102.3, 100.7, 99.8, 99.5, 98.0, 78.8–78.4,
73.3–73.2, 72.0, 71.1–71.0, 70.3–69.9, 69.7–69.5, 66.9–66.8,
65.9, 65.6, 65.4, 65.2, 63.4, 62.5, 61.1–61.0, 50.1, 50.1, 44.6.
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2020 Org. Biomol. Chem., 2020, 18, 6086–6094 | 6091
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
7 
Ju
ly
 2
02
0.
 D
ow
nl
oa
de
d 
on
 9
/2
4/
20
20
 5
:2
0:
41
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
ESI-MS m/z calcd for C191H320N12O145Cl: 5087.2; found: 2567.0
[M + 2Na]2+, 1781.1 [M + 3Na]3+, and 1294.6 [M + 4Na]4+.
D3-βMan9-Cl (16). Nonasaccharide 13 (22.0 mg, 14.23 μmol)
and 14 (1.6 mg, 3.59 μmol) were dissolved in H2O/DMSO (1 : 1,
0.5 mL). Fresh solutions of CuSO4·5H2O (1.80 μmol), TBTA
(3.59 μmol) and sodium ascorbate (5.39 μmol) were added to a
sealed microwave vial. The solution was heated at 60 °C in a
microwave oven for 30 min. A metal scavenger resin,
QuadrasilMP, was added to the reaction solution and stirred
for 20 min at rt. After that, the mixture was filtered and the
resulting solution was purified by size-exclusion chromato-
graphy (Sephadex G-50, H2O/MeOH 9 : 1) yielding the glyco-
cluster 16 (14.8 mg, 2.91 μmol, 81%) as a white amorphous
solid. 1H-NMR (400 MHz, D2O) δ: 8.05 (s, 3H, 3Htriazole), 5.42
(br s, 1H, 3H-1), 5.34–5.28 (m, 6H, 6H-1), 5.15 (br s, 3H, 3H-1),
5.09–5.03 (m, 9H, 9H-1), 4.87 (br s, 3H, 3H-1), 4.67 (m, 3H,
OCH2CHHN), 4.61–4.56 (br s, 6H, H-1, OCHHCtriazole),
4.18–3.56 (m, 198H). 13C-NMR (100 MHz, D2O) δ: 144.1,
125.5, 102.3, 102.2, 100.8, 100.7, 100.6, 99.9, 99.5, 98.0,
80.9, 78.9–78.5, 74.0, 73.3–73.2, 72.7, 71.1, 70.8, 70.3–69.9,
69.7–69.5, 68.3–67.7, 66.9–66.8, 65.6–65.2, 63.5, 62.5,
61.1–61.0, 50.3, 44.7, 43.2. ESI-MS m/z calcd for
C191H320N9O145Cl: 5080.7; found: 2561.1 [M + 2Na]
2+, 1715.2
[M + 3Na]3+, and 1293.5 [M + 4Na]4+.
D3-βMan9-N3 (18). To a solution of glycocluster 16 (20.0 mg,
3.94 μmol) in DMF (1 mL) sodium azide (2.6 mg, 39.36 μmol)
was added. The mixture was stirred at 70 °C for 2 days. After
that time, the solvent was evaporated under vacuum and the
crude was purified using Amicon Ultra-15 centrifugal filters
(MWCO 3 kDa), yielding the glycocluster 18 (20 mg, 3.94 μmol,
quant.) as a white amorphous solid. 1H-NMR (400 MHz, D2O)
δ: 8.05 (s, 3H, 3Htriazole), 5.41 (br s, 1H, 3H-1), 5.34–5.29 (m,
6H, 6H-1), 5.15 (br s, 3H, 3H-1), 5.07–5.03 (m, 9H, 9H-1),
under D2O (3H, 3H-1), 4.68 (m, 3H, OCHHCtriazole), 4.60–4.55
(m, 6H, H-1, OCH2CHHN), 4.12–3.46 (m, 198H).
13C-NMR
(100 MHz, D2O) δ: 144.1, 125.5, 102.3, 102.2, 100.8, 100.7,
100.6, 99.9, 99.5, 98.0, 80.9, 78.9–78.4, 74.0, 73.3–73.2, 72.7,
72.0, 71.1, 70.3–69.9, 69.7–69.5, 69.2, 68.3, 67.7, 66.9–66.8,
65.6–65.2, 63.5, 62.4, 61.1–61.0, 50.2, 50.1, 44.7. ESI-MS m/z
calcd for C191H320N12O145: 5087.2; found: 2566.5 [M + 2Na]
2+,
1717.9 [M + 3Na]3+, and 1293.9 [M + 4Na]4+.
αMan9-fluorescein (20). To a solution of the FAM-alkyne
6-isomer 19 (2.67 mg, 6.48 μmol) and the epitope αMan9 12
(5 mg, 3.24 μmol) in DMSO (300 μL), another solution of CuBr
(3.24 μmol) and TBTA (6.48 μmol) in the same solvent (150 μL)
was added. The reaction mixture was stirred on at rt.
Thereafter, a metal scavenger resin, QuadrasilMP, was added
to the reaction solution and stirred for 20 min at rt. After that,
the mixture was filtered and the resulting solution was purified
by size-exclusion chromatography (Sephadex LH-20, H2O/
MeOH 9 : 1), yielding the fluorescent probe 20 (6.3 mg, quant.)
as an orange amorphous solid. 1H-NMR (400 MHz, D2O) δ:
8.22–7.87 (m, 3H), 7.68 (br s, 1H), 7.30–7.07 (m, 2H), 6.87–6.54
(m, 4H), 5.40–5.24 (m, 3H, 3H-1), 5.11 (br s, 1H, 1H-1), 5.04 (br
s, 3H, 3H-1), under D2O (2H, 2H-1), 4.64 (m, 2H), 4.12–3.57
(m, 58H). 13C-NMR (100 MHz, selected data obtained from
HSQC, D2O) δ: 131.2, 128.2, 128.2, 127.9, 121.7, 103.0, 102.2,
100.8, 100.6, 100.0, 99.5, 98.0, 78.8–78.5, 73.2, 73.2, 72.7, 71.1,
71.1, 70.3–70.0, 69.6, 66.9, 66.8, 66.6, 65.7, 65.5, 65.2,
61.2–61.0, 50.2. ESI-MS: m/z calcd for C80H110N4O52: 1958.6,
found: 978.1 [M − 2H]2−.
βMan9-fluorescein (21). To a solution of the FAM-alkyne
6-isomer 19 (6.6 mg, 10.36 μmol) and the epitope β-Man9 13
(8 mg, 5.18 μmol) in DMSO (300 μL), another solution of CuBr
(5.18 μmol) and TBTA (10.36 μmol) in the same solvent
(150 μL) was added. The reaction mixture was stirred on at rt.
Thereafter, a metal scavenger resin, QuadrasilMP, was added
to the reaction solution and stirred for 20 min at rt. After that,
the mixture was filtered and the resulting solution was purified
by size-exclusion chromatography (Sephadex LH-20, H2O/
MeOH 9 : 1), yielding the fluorescent probe 21 (10.1 mg,
quant.) as an orange amorphous solid. 1H-NMR (400 MHz,
D2O) δ: 8.05–7.98 (m, 2H), 7.94 (m, 1H), 7.57 (br s, 1H),
7.15–7.07 (m, 2H), 6.69–6.63 (m, 4H), 5.37 (br s, 1H, H-1),
5.31–5.26 (m, 2H, 2H-1), 5.10 (br s, 1H, H-1), 5.06–5.00 (m, 4H,
4H-1), 4.65 (m, 2H, CH2Ctriazole), 4.59 (m, 2H, CH2CH2N), 4.49
(br s, 1H, H-1), 4.21 (m, 1H), 4.12–4.05 (m, 6H), 4.03–3.92 (m,
6H), 3.90–3.60 (m, 42H), 3.41 (m, 1H). 13C-NMR (100 MHz,
selected data obtained from HSQC, D2O) δ: 131.0, 128.2, 128.2,
127.9, 121.7, 103.0, 102.3, 102.1, 100.7, 100.5, 99.9, 99.5, 97.9,
81.0, 78.9, 78.6, 78.5, 78.4, 74.0, 73.2–73.1, 72.6, 71.1,
70.3–69.9, 69.4, 68.4, 66.9–66.8, 65.6–65.4, 61.1–60.9, 50.3.
ESI-MS: m/z calcd for C80H110N4O52: 1958.6, found: 1982.3
[M − H]−, and 1002.1 [M − 2H]2−.
D3-αMan9-fluorescein (22). To a solution of the FAM-alkyne
6-isomer 19 (1.3 mg, 3.14 μmol) and the trivalent glycocluster
of αMan9 17 (8 mg, 1.57 μmol) in DMSO (400 μL), another
solution of CuBr (1.57 μmol) and TBTA (3.14 μmol) in the
same solvent (200 μL) was added. The reaction mixture was
stirred on at rt. Thereafter, a metal scavenger resin,
QuadrasilMP, was added to the reaction solution and stirred
for 20 min at rt. After that, the mixture was filtered and the
resulting solution was purified by size-exclusion chromato-
graphy (Sephadex LH-20, H2O/MeOH 9 : 1), yielding the fluo-
rescent probe 22 (8.7 mg, quant.) as an orange amorphous
solid. 1H-NMR (400 MHz, D2O) δ: 8.06–7.78 (m, 6H), 7.57 (br s,
1H), 7.07–6.88 (m, 2H), 6.62–6.42 (m, 4H), 5.35–5.16 (m, 9H,
9H-1), 5.06 (br s, 3H, 3H-1), 4.96 (br s, 9H, 9H-1), under D2O
(6H, 6H-1), 4.55–4.29 (m, 6H), 4.07–3.11 (m, 213H). 13C-NMR
(100 MHz, selected data obtained from HSQC, D2O) δ: 126.8,
122.9, 102.9, 102.3, 100.7, 99.8, 99.5, 98.0, 78.8–78.4,
73.3–73.2, 72.0, 71.1–71.0, 70.3–69.9, 69.7–69.5, 66.9–66.8,
65.9, 65.6, 65.4, 65.2, 63.4, 62.5, 61.1–61.0, 50.1. ESI-MS: m/z
calcd for C215H335N13O151: 5514.9, found: 2749.4 [M − 2H]2−,
and 1833.1 [M − 3H]3−.
D3-βMan9-fluorescein (23). To a solution of the FAM-alkyne
6-isomer 19 (2.3 mg, 5.5 μmol) and the trivalent glycoclusters
of βMan9 18 (14 mg, 2.75 μmol) in DMSO (180 μL), another
solution of CuBr (2.75 μmol) and TBTA (5.5 μmol) in the same
solvent (90 μL) was added. The reaction mixture was stirred on
at rt. Thereafter, a metal scavenger resin, QuadrasilMP, was
added to the reaction solution and stirred for 20 min at rt.
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After that, the mixture was filtered and the resulting solution
was purified by size-exclusion chromatography (Sephadex
LH-20, H2O/MeOH 9 : 1), yielding the fluorescent probe 23
(15.0 mg, quant.) as an orange amorphous solid. 1H-NMR
(400 MHz, D2O) δ: 8.02–7.80 (m, 6H), 7.54 (br s, 1H), 7.01–6.87
(m, 2H), 6.58–6.46 (m, 4H), 5.40–5.30 (m, 6H, 6H-1), 5.21 (m,
6H, 6H-1), 5.06 (br s, 3H, 3H-1), 4.96 (m, 9H, 9H-1), 4.53–4.41
(m, 12H, 3H-1), 4.29 (br s, 6H), 4.07–3.05 (m, 204H). 13C-NMR
(100 MHz, selected data obtained from HSQC, D2O) δ: 131.0,
129.6, 128.5, 124.0, 122.4, 103.8, 102.3, 102.2, 100.8, 100.7,
100.6, 99.9, 99.5, 98.0, 80.9, 78.9–78.4, 74.0, 73.3–73.2, 72.7,
72.0, 71.1, 70.3–69.9, 69.7–69.5, 69.2, 68.3, 67.7, 66.9–66.8,
65.6–65.2, 63.5, 62.4, 61.1–61.0, 50.1 (OCH2CH2N). ESI-MS: m/z
calcd for C215H335N13O151: 5514.9, found: 2748.5 [M − 2H]2−,
and 1830.8 [M − 3H]3−.
DC-SIGN ECD expression
DC-SIGN ECD expression and production was performed as
previously described. Briefly, the DC-SIGN ECD protein is
expressed as inclusion bodies in E. coli, refolded and purified
using a mannose affinity chromatography step followed by a
size exclusion.28,29 Both steps ensure respectively the selection
of correctly folded and oligomerized protein.
DC-SIGN binding assays by fluorescence polarization
The fluorescence polarization measurements were performed
in 384-well microplates (black polystyrene, non-treated,
Corning), using a TRIAD multimode microplate reader (from
Dynex) with excitation and emission wavelengths of 485 and
535 nm, respectively. Fluorescent compounds 20–23 and
DC-SIGN-ECD were dissolved in Tris buffer (25 mM, pH 8,
150 mM NaCl, 4 mM CaCl2). 15 μL of a 20 nM fluorescent
ligand solution were transferred to each well. Then, 15 μL of
protein solutions, with concentrations ranging from 75 nM to
28 μM, were added to the microplate wells. Therefore, the total
sample volume in each well was 30 μL. The microplate was
shaken in the dark for 5 min, before reading. Blank wells con-
tained 15 μL of the DC-SIGN-ECD solution and 15 μL of Tris
buffer, and their measurements were subtracted from all
values. All experiments on samples were performed in repli-
cates of three.
Wells containing 15 μL of the 20 nM fluorescence com-
pound solution and 15 μL of Tris buffer afforded the back-
ground polarization of the fluorescent molecule, in the
absence of protein. This value was subtracted from the polariz-
ation values of all the samples, giving the increment in the
fluorescence polarization (ΔP). The average ΔP values of three
replicate wells were plotted against the concentration of
DC-SIGN-ECD, and the resulting curve was fitted to the
equation for a one-site binding model: y = ΔPmaxx/[KD + x]
where ΔPmax is the maximal value of ΔP and KD is the dis-
sociation constant of the interaction.
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